Metastatic Castration-sensitive Prostate Cancer Clinical Trials

15 clinical trials for Metastatic Castration-sensitive Prostate Cancer across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — RECRUITING · PHASE3
• A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01). — RECRUITING · PHASE3
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer — RECRUITING · PHASE1
• C3441052 - TALAPRO-3: A Phase 3, Randomized, Double-Blind Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer — TERMINATED · PHASE3
• Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — ACTIVE_NOT_RECRUITING · PHASE3
• Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy — COMPLETED · PHASE2
• C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3) — TERMINATED · PHASE3
• Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland — COMPLETED
• A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) — COMPLETED
• Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE1
• A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer — COMPLETED
• TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer — COMPLETED · PHASE3
• Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan — OTHER · PHASE4

Refine this search